CHRS Coherus Oncology, Inc.companySEC Filings & Insider Trading Activity 2026
Latest Coherus Oncology, Inc. (CHRS) SEC EDGAR filings in 2026, including the most recent 10-K annual report filed on March 9, 2026, a 10-Q quarterly report filed on May 11, 2026, an 8-K current report filed on August 5, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for Coherus Oncology, Inc. (CHRS) (SEC CIK 1512762), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
Go deeper on Coherus Oncology, Inc.
Ask AI about CHRS filings. Chat with the 10-K, 10-Q, and 8-K for instant answers on financials, risks, and guidance.
Track institutional money. See which funds are building or cutting CHRS positions, quarter over quarter.
Catch cross-signals. Spot when insider buying, fund accumulation, and activist stakes line up on CHRS.
Recent 8-K FilingsCurrent Reports
AI-powered analysis of Coherus Oncology, Inc. (CHRS) 8-K current reports disclosing material events.
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Aug 5, 2026 | - | - | - |
8-K | Jun 15, 2026 | - | - | - |
8-K | Jun 1, 2026 | - | - | |
8-K | May 11, 2026 | - | - | |
10-Q | May 11, 2026 | Mar 31, 2026 | - | |
10-K | Mar 9, 2026 | Dec 31, 2025 | - | |
8-K | Mar 9, 2026 | - | Analysis | - |
8-K | Feb 17, 2026 | - | - | |
8-K | Feb 4, 2026 | - | - | |
8-K | Jan 23, 2026 | - | - | |
8-K | Jan 13, 2026 | - | - | |
10-Q | Nov 6, 2025 | Sep 30, 2025 | - | |
10-Q | Aug 7, 2025 | Jun 30, 2025 | - | |
10-Q | May 12, 2025 | Mar 31, 2025 | - | |
10-K | Mar 17, 2025 | Dec 31, 2024 | - | |
SC 13G | Nov 13, 2024 | - | - | |
10-Q | Nov 6, 2024 | Sep 30, 2024 | - | |
10-Q | Aug 8, 2024 | Jun 30, 2024 | - | |
10-Q | May 9, 2024 | Mar 31, 2024 | - | |
10-K | Mar 15, 2024 | Dec 31, 2023 | - | |
10-Q | Nov 6, 2023 | Sep 30, 2023 | - | |
10-Q | Aug 2, 2023 | Jun 30, 2023 | - | |
SC 13G | May 19, 2023 | - | - | |
10-Q | May 8, 2023 | Mar 31, 2023 | - | |
10-K | Mar 6, 2023 | Dec 31, 2022 | - |
13F Fund Holdings: Quarterly Trend
Latest: Q1 2026Aggregate CHRS share value held by 13F filers tracked by SignalX, by quarter.
- Two Sigma Investments+1.80M (+357%)
- Goldman Sachs Group+389.0K (+127%)
- AQR Capital Management+320.3K (+36%)
- Citadel Advisors LLC+239.9K (+157%)
- Bank of America Corp+212.4K (+190%)
- Millennium Management348.5K (-53%)
- BlackRock197.6K (-2%)
- Citigroup140.5K (-73%)
- Wells Fargo & Co79.3K (-67%)
- Morgan Stanley50.9K (-20%)
- Dimensional Fund Advisors+35.4K
- Prudential Financial+16.1K
- Vanguard Group Inc−10.03M
- Invesco Ltd−380.0K
- JPMorgan Chase & Co−51.2K
- StoneX Group Inc.−11.0K
Source: 13F-HR filings on SEC EDGAR (aggregated from 131 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe.
Frequently Asked Questions
What are the latest CHRS SEC filings in 2026?
Coherus Oncology, Inc. (CHRS) has filed a 10-K annual report on March 9, 2026, a 10-Q quarterly report on May 11, 2026, an 8-K current report on August 5, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did CHRS file its most recent 10-K annual report?
Coherus Oncology, Inc. (CHRS) filed its most recent 10-K annual report on March 9, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view CHRS 10-Q quarterly reports?
Coherus Oncology, Inc. (CHRS)'s most recent 10-Q quarterly report was filed on May 11, 2026. SignalX displays every CHRS 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has CHRS filed recently?
Coherus Oncology, Inc. (CHRS)'s most recent 8-K was filed on August 5, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find CHRS insider trading activity (Form 4)?
SignalX aggregates every CHRS Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does CHRS file with the SEC?
Coherus Oncology, Inc. (CHRS) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new CHRS filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Coherus Oncology, Inc. (CHRS).
What is CHRS's SEC CIK number?
Coherus Oncology, Inc. (CHRS)'s SEC CIK (Central Index Key) number is 1512762. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1512762 to look up all CHRS filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Stay on top of Coherus Oncology, Inc. SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 78+ filings.